Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
etoposide + carboplatin + paclitaxel
- Development stage
- Unknown
- Lead developer
- Bristol Myers Squibb
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Administration
- Intravenous
01
Overview
This is a combination chemotherapy regimen consisting of three cytotoxic agents—etoposide, carboplatin, and paclitaxel—used primarily in the treatment of small-cell lung cancer (SCLC). Each drug has a distinct mechanism of action: - Etoposide is a topoisomerase II inhibitor that induces DNA strand breaks and prevents cell division. - Carboplatin is a platinum-based compound that forms DNA crosslinks, inhibiting DNA synthesis and function. - Paclitaxel stabilizes microtubules, preventing their depolymerization and thereby blocking cell division. The combination leverages these complementary mechanisms to enhance antitumor efficacy. Clinical studies have shown this regimen can be administered at full doses with manageable toxicity profiles. It has demonstrated high response rates in both limited-stage and extensive-stage SCLC patients[1][2]. Myelosuppression (notably neutropenia) is the primary dose-limiting toxicity[1].
- Brand names
- TaxolParaplatinEtopophosVepesid
- Other names
- PCE regimenPaclitaxel-Carboplatin-Etoposide
02
Targets
TOP2A (DNA topoisomerase II)DNATUBB (Tubulin (alpha and beta subunits))
Beyond the preview
Go deeper on etoposide + carboplatin + paclitaxel.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on etoposide + carboplatin + paclitaxel.